Pepvise
Compound profile· Compounds

Epithalon, what the evidence shows

By The PepVise Editorial Team · Reviewed July 6, 2026 · 15 min read

Evidence Ledger for epithalon (epitalon, AEDG): a synthetic pineal tetrapeptide marketed for telomerase activation and longevity. What the cell studies and the Russian human cohorts actually show, and what they lack.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.
The PepVise Editorial Teamfrom the house style guide
Editorial reference
Primary literature

PubMed search, 'epitalon', plus the Russian Khavinson cohorts

Epithalon is a case where the search itself is the honest starting point, because it shows two things side by side: a coherent cell-biology story about telomerase, independently replicated for the first time in 2025, and a striking but almost single-laboratory human cohort record out of Russia. Seeing both halves directly tells the reader more than any vendor page, including ours.

Reference reading

The texts we read alongside the papers.

  1. 01
    Primary literature

    PubMed saved search, 'epitalon' and 'epithalon'

    A PubMed search surfaces the defining shape of the evidence: a modest body of cell and animal work on telomerase activation, dominated by the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson, plus a 2025 Biogerontology paper that independently replicated telomere lengthening in human cell lines. It is the fastest way to see how concentrated the source of the data is.

  2. 02
    Reference text

    Williams Textbook of Endocrinology (14th ed.)

    The pineal gland, melatonin, and the neuroendocrine regulation that the epithalon hypothesis rests on are standard endocrinology. Williams supplies that background without the longevity-marketing layer vendor pages add. Read it for pineal biology, not for any use guidance.

  3. 03
    Popular-science background

    Outlive, Peter Attia, MD (with Bill Gifford)

    Attia's recurring principle, that a mechanistic or surrogate finding is not the same as a hard clinical endpoint, applies to epithalon exactly. Telomere length is a surrogate marker; a longer, healthier life is the endpoint. The book does not cover epithalon; the reasoning discipline is the point.

Methodology

How we read the literature

Evidence tier
We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage
Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status
We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain
Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
Frequently asked

The questions readers actually bring us.

Is epithalon FDA-approved?
No. Epithalon has no FDA-approved indication and is not registered as a medicine outside certain former-Eastern-Bloc settings. In the US and EU it circulates as a research chemical labeled for non-human use. There is no independently run randomized clinical-endpoint trial supporting its marketed longevity uses.
Does epithalon actually lengthen telomeres?
In cell culture, there is evidence for it. Khavinson and colleagues reported in 2003 that epithalon increased telomerase activity and telomere length in human somatic cells, and an independent group replicated telomere lengthening in human cell lines in 2025. Whether this translates into a longer or healthier life in living humans is not established. Telomere length is a surrogate marker, not an outcome.
How strong is the human evidence for epithalon?
It rests largely on cohort work from a single institute. The most cited human data come from Khavinson's group in St. Petersburg, reporting lower mortality in elderly subjects given pineal and thymic peptides over a multi-year follow-up. The results are striking but have not been independently replicated by unaffiliated groups in over twenty years, which is the central open question.
Is epithalon the same as epithalamin?
Not exactly. Epithalamin is a natural peptide extract of the pineal gland; epithalon (AEDG) is the synthetic tetrapeptide modeled on it. Much of the famous human cohort data used epithalamin, the extract, while the telomerase cell studies used the synthetic tetrapeptide. This distinction matters when reading claims, because the human and cell evidence do not always concern the identical substance.
Why does PepVise not give an epithalon dose?
Because we describe the literature and do not recommend administration. The injection schedules repeated online come from Russian protocols and forums, not from internationally replicated dose-finding trials. We describe what has been published and explain how these research chemicals are regulated separately.
What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Further reading

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min readCompounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min readCompounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.